Pelvic Pain
Conditions
Interventions
Therapeutic Ultrasound - experimental group: Therapeutic ultrasound treatment will be performed by a trained physiotherapist once a week for 10 consecutive weeks, with a frequency of 1 Mhz, intensity
Drug
Device
E02.565.280.945
Sponsors
Faculdade de Medicina de Ribeirão Preto - FMRP-USP
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Women older than eighteen years and not menopausal with clinical diagnosis of abdominal myofascial syndrome with presence of only one active trigger point and pain above four point four (moderate pain) in the visual analogue scale (VAS) and without previous treatments.
Exclusion criteria
Exclusion criteria: Pregnant women with hip prosthesis, neoplasias in the abdomino-pelvic region, with severe osteoporosis, copper IUDs, abdominal varicose veins, cognitive deficits that make the questionnaires difficult to comprehend, women with anticoagulation or hemorrhagic disorders, local or systemic infections, allergy to anesthetics, acute muscle trauma, extreme fear of needles, history of complaints of chronic musculoskeletal pain such as fibromyalgia, chronic fatigue or diabetes. Also included in the exclusion criteria are those who use chronic painkillers, anti inflammatories, and tricyclic antidepressants who have used aspirin within three days prior to injection, all patients with suspected interstitial cystitis, bowel syndrome irritable or other disease that justifies or contributes to CPP, will also be part of the criteria for exclusion of endometrioma or hernia evidenced by ultrasound of the abdominal wall, abdominal wall infections and women who are missing after the start of treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1 - clinical pain: Improvement of clinical pain in the experimental group is expected. This outcome will be assessed using the analogue, numerical categorical and McGill pain questionnaires, in the periods prior to the start of treatment, after the end of the treatment will be evaluated in the periods of 1 week, 1 month, 3 months and 6 months.;Expected outcome 2 - experimental pain: We hope to improve experimental pain in the experimental group. This outcome will be assessed through algometry, in the periods before the start of treatment, after the end of the treatment will be evaluated in the periods of 1 week, 1 month, 3 months and 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 3 - quality of life: It is expected to improve the quality of life in the experimental group. This outcome will be evaluated through the SF-36 questionnaire, in the periods before the start of treatment, after the end of the treatment will be evaluated in the periods of 1 week, 1 month, 3 months and 6 months.;Expected outcome 4- manifestation of adverse events: Non-manifestation of adverse events in the experimental group is expected. This outcome will be assessed through the reports of the volunteers themselves during the treatment period. | — |
Countries
Brazil
Contacts
Public ContactMaria Dalla Vecchia Vieira
Faculdade de Medicina de Ribeirão Preto - FMRP-USP
Outcome results
None listed